Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20206735 | 0.89 | ALDH1A1 (0.39) | ESR1ESR2ALDH1A1RORCMCL1 | |
| SCHEMBL19646432 | 0.82 | ALDH1A1 (0.36) | ESR1ESR2ALDH1A1RORCMCL1 | |
| SCHEMBL21324857 | 0.78 | NPC1 (0.43) | ALDH1A1MCL1 | |
| SCHEMBL24866060 | 0.76 | CNR2 (0.40) | ESR1ESR2ALDH1A1 | |
| SCHEMBL25085263 | 0.73 | LYN (0.31) | — | |
| SCHEMBL9605457 | 0.73 | ALDH1A1 (0.44) | ALDH1A1RORC | |
| SCHEMBL24880084 | 0.70 | ALDH1A1 (0.41) | ALDH1A1RORC | |
| SCHEMBL24004027 | 0.68 | ESR1 (0.50) | ESR1ESR2ALDH1A1 | |
| SCHEMBL21164691 | 0.68 | ESR1 (0.46) | ESR1ESR2ALDH1A1 | |
| SCHEMBL22955761 | 0.68 | ESR1 (0.46) | ESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | ESR1 1245/4885ESR2 1401/4885ALDH1A1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.